AlphAIAlphAI — Financial news for AI agents
tradingview.com$KRRO

Korro Bio 3Q 2026: Revenue $0, EPS ($0.98) — 10-Q Summary

Korro Bio reported no revenue in Q3 2026, down from $1.1M a year earlier, with a net loss of $17.55M, a 2.8% improvement. EPS loss narrowed to $0.98. R&D costs fell to $12.1M. KRRO-121 trial dosing began, and KRRO-111 submission is expected in 2027. Cash runway extends to mid-2028, according to the company.

Original reporting
tradingview.com
Published Nov 5, 2026, 12:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Korro Bio 3Q 2026: Revenue $0, EPS ($0.98) — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$KRROBearishMed
01

Why it matters

The Q3 2026 filing reveals zero collaboration revenue and a narrowed net loss, signaling ongoing trial risk but improved cost structure.

02

Market read

The earnings release provides fresh data for traders evaluating small‑cap biotech exposure.

03

What to watch

Cash runway extends into 2028, providing liquidity to fund upcoming Phase 1/2 trials.

Relevance 6/10Novelty 7/10Timing: today

Background

Korro Bio (KRRO) is a clinical‑stage biotech focused on KRRO‑121, KRRO‑111, and KRRO‑110 programs.

Company-level read

Ticker impact

$KRROBearishHigh confidence
Context

Q3 2026 10-Q shows zero collaboration revenue and narrowed net loss, new financial data for Korro Bio.

Expected impact

likely pressure as investors price in zero revenue and ongoing losses

Evidence & confidence

The company reported no revenue and a net loss of $17.55M, indicating limited short‑term upside despite cost reductions.

Market effects

Sector

Biotech sector may see modest caution as a peer reports zero revenue, highlighting trial risk.

Regional

Limited to US small‑cap biotech investors.

Global

Low; impact confined to niche biotech investors.

Counterpoint

What could challenge this read

Cost reductions could set the stage for a future upside if upcoming trials succeed.

Key entities

  • company
    Korro Bio

    Biotech company reporting Q3 2026 results.

Read at source← All news

Related articles

$KRROMedAI 8/10

Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency

Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency • Repeat dose mouse studies achieved >95% SERPINA1 mRNA editing, sustained restoration of circulating function

SEC EDGAR 8-K
$KRROMedAI 8/10

H.C. Wainwright reiterates Korro Bio stock rating on trial dosing

H.C. Wainwright reiterated a Buy rating and $15.00 price target for Korro Bio (KRRO) after the company dosed the first cohort in its Phase 1/2 trial for KRRO-121. The stock is down 77% over the past year, trading at $9.97. Korro Bio has a strong current ratio of 9.55 and more cash than debt. The ANCHOR trial is expected to take about a year, with primary completion estimated for the second half of 2027.

investing.com